Concurrent crizotinib and whole-brain radiation for brain metastases in ALK-positive lung adenocarcinoma. (October 2014)

• Record Type: Journal Article
• Authors: Pinto, Ian G; Lee, Mijung; Graziano, Stephen; Lacombe, Michael; Gajra, Ajeet
• Is Part Of: Lung cancer management. Volume 3:Number 5(2014)
• Page Start: 369
• Page End: 371
• Publication Date: 2014-10
• Subjects: ALK -- concurrent crizotinib radiation -- crizotinib -- lung cancer -- oral-targeted therapy -- radiation; Lungs -- Cancer -- Periodicals; 616.99424
• DOI: 10.2217/lmt.14.28
• Languages: English
• ISSNs: 1758-1966

Abstract

SUMMARY : Crizotinib is now used for ALK-positive adenocarcinoma of the lung. To the best of our knowledge it has not been used concurrently with radiation. We report the first case where a patient safely tolerated crizotinib with concurrent whole-brain radiation therapy for brain metastases in ALK-positive adenocarcinoma of the lung. The patient had a good response to the combination with improved performance status.